Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

The requested reference [375b090a9fa2f4daf354f49bd11c1a3d84ee315f] no longer exists in our database. It has been replaced by the current reference: [f38741028806983282ed2284238822986cd3d57d]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and in HIV-infected adults.
Epistemonikos ID: 35fdbdaf5a09a8d15b3942619cd670867cb1a190
First added on: Jul 21, 2023